CD8A and neoplasm: In addition, recent studies reported that the anti‐tumor immunity effects of PARPi were mediated by CD8+ T cell activation.[11, 31, 32] Based on these findings, we next determined whether the combination of XL413 with Olaparib could potentiate the activation of CD8+ T cells, we utilized a LacZ assay to assess the activation of OVA‐specific CD8+ T cell hybridoma B3Z cells co‐cultured with ID8‐OVA or HGS1‐OVA cells.[33] The results showed that the combination treatment significantly enhanced LacZ activity (Figure 5D), a reporter for indicating T‐cell activation.